Table 6.

Adverse events (safety population)

Study	Ceftaroline group	Control group	Ceftaroline group	Control group	Ceftaroline group	Control group	Ceftaroline group	Control group
	Any adverse events, n (%)		Diarrhea, n (%)		Headache, n (%)		Insomnia, n (%)
File et al............, 2011 [10]	119/298 (39.9)	136/308 (44.2)	14/298 (4.7)	7/308 (2.3)	10/298 (3.4)	4/308 (1.3)	9/298 (3.0)	6/308 (1.9)
Low et al., 2011 [11]	196/315 (53.7)	145/307 (47.2)	12/315 (3.8)	9/307 (2.9)	11/315 (3.5)	5/307 (1.6)	10/315 (3.2)	8/307 (2.6)
File et al, 2010 [13]	288/613 (47.0)	281/615 (45.7)	26/613 (4.2)	16/615 (2.6)	21 /613 (3.4)	9/615 (1.5)	19/613 (3.1)	14/615 (2.3)
Zhong et al..., 2015 [14]	172/381 (45.1)	163/383 (42.7)	24/381 (6.3)	13/383 (3.4)	6/381 (1.6)	9/383 (2.4)	–	–
	Nausea, n (%)		Phlebitis, n (%)		Hypertension, n (%)		Hypokalaemia, n (%)
File et al, 2011 [10]	8/298 (2.7)	8/308 (2.6)	7/298 (2.3)	5/308 (1.6)	6/298 (2.0)	8/308 (2.6)	4/298 (1.3)	10/308 (3.2)
Low et al, 2011 [11]	6/315 (1.9)	6/307 (2.0)	10/315 (3.2)	8/307 (2.6)	8/315 (2.5)	8/307 (2.6)	10/315 (3.2)	5/307 (1.6)
File et al, 2010 [13]	14/613 (2.3)	14/615 (2.3)	17/613 (2.8)	13/615 (2.1)	14/613 (2.3)	16/615 (2.6)	14/613 (2.3)	15/615 (2.4)
Zhong et al, 2015 [14]	8/381 (2.1)	3/383 (0.8)	–	–	–	–	5/381 (1.3)	4/383 (1.1)